First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population

This publication has 30 references indexed in Scilit:

• Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab
  JAMA Cardiology, 2019
• Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
  New England Journal of Medicine, 2018
• Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
  Future Cardiology, 2018
• Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe
  Clinical Chemistry, 2018
• Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
  The Lancet, 2017
• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
  New England Journal of Medicine, 2017
• Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
  European Heart Journal, 2017
• Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
  New England Journal of Medicine, 2017
• Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents
  European Heart Journal, 2016
• PCSK9 inhibitors and cardiovascular disease
  Current Opinion in Lipidology, 2015